AAAAAA

   
Results: 1-21 |
Results: 21
Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy
Authors: Czuczman, MS Grillo-Lopez, AJ McLaughlin, P White, CA Saleh, M Gordon, L LoBuglio, AF Rosenberg, J Alkuzweny, B Maloney, D
Citation: Ms. Czuczman et al., Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy, ANN ONCOL, 12(1), 2001, pp. 109-114
Clinical impact of rituximab in managing B-cell lymphomas
Authors: Grillo-Lopez, AJ McLaughlin, P Wey, K Dallaire, BK Nasazideh, H Eldredge, E Leonerd, JE White, CA Cabanillas, F
Citation: Aj. Grillo-lopez et al., Clinical impact of rituximab in managing B-cell lymphomas, ONCOLOGY-NY, 15(3), 2001, pp. 11
Rituximab using a thrice weekly dosing schedule in B-Cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity
Authors: Byrd, JC Murphy, T Howard, RS Lucas, MS Goodrich, A Park, K Pearson, M Waselenko, JK Ling, G Grever, MR Grillo-Lopez, AJ Rosenberg, J Kunkel, L Flinn, IW
Citation: Jc. Byrd et al., Rituximab using a thrice weekly dosing schedule in B-Cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity, J CL ONCOL, 19(8), 2001, pp. 2153-2164
Antibody-targeted immunotherapy for treatment of malignancy
Authors: White, CA Weaver, RL Grillo-Lopez, AJ
Citation: Ca. White et al., Antibody-targeted immunotherapy for treatment of malignancy, ANN R MED, 52, 2001, pp. 125-145
Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a
Authors: Davis, TA Maloney, DG Grillo-Lopez, AJ White, CA Williams, ME Weiner, GJ Dowden, S Levy, R
Citation: Ta. Davis et al., Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a, CLIN CANC R, 6(7), 2000, pp. 2644-2652
Correspondence re: T. Davis et al, therapy of B-cell lymphoma with anti-CD20 antibodies can result in loss of CD20 antigen expression. Clin. Cancer Res., 5 : 611-615, 1999.
Authors: Grillo-Lopez, AJ Kunkel, L
Citation: Aj. Grillo-lopez et L. Kunkel, Correspondence re: T. Davis et al, therapy of B-cell lymphoma with anti-CD20 antibodies can result in loss of CD20 antigen expression. Clin. Cancer Res., 5 : 611-615, 1999., CLIN CANC R, 6(1), 2000, pp. 317-318
Response criteria for NHL: Importance of 'normal' lymph node size and correlations with response rates
Authors: Grillo-Lopez, AJ Cheson, BD Horning, SJ Peterson, BA Carter, WD Varns, CL Klippenstein, DL Shen, CD
Citation: Aj. Grillo-lopez et al., Response criteria for NHL: Importance of 'normal' lymph node size and correlations with response rates, ANN ONCOL, 11(4), 2000, pp. 399-408
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma:Safety and efficacy of re-treatment
Authors: Davis, TA Grillo-Lopez, AJ White, CA McLaughlin, P Czuczman, MS Link, BK Maloney, DG Weaver, RL Rosenberg, J Levy, R
Citation: Ta. Davis et al., Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma:Safety and efficacy of re-treatment, J CL ONCOL, 18(17), 2000, pp. 3135-3143
Rituximab: An insider's historical perspective
Authors: Grillo-Lopez, AJ
Citation: Aj. Grillo-lopez, Rituximab: An insider's historical perspective, SEMIN ONCOL, 27(6), 2000, pp. 9-16
A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia
Authors: Saleh, MN Gutheil, J Moore, M Bunch, PW Butler, J Kunkel, L Grillo-Lopez, AJ LoBuglio, AF
Citation: Mn. Saleh et al., A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia, SEMIN ONCOL, 27(6), 2000, pp. 99-103
Anti-CD20 monoclonal antibodies as novel treatments for non-Hodgkin's lymphoma
Authors: White, CA Larocca, A Grillo-Lopez, AJ
Citation: Ca. White et al., Anti-CD20 monoclonal antibodies as novel treatments for non-Hodgkin's lymphoma, PHARM SCI T, 2(3), 1999, pp. 95-101
Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with Zevalin, a Y-90-labeled anti-CD20 monoclonal antibody
Authors: Wiseman, GA White, CA Witzig, TE Gordon, LI Emmanouilides, C Raubitschek, A Janakiraman, N Gutheil, J Schilder, RJ Spies, S Silverman, DHS Grillo-Lopez, AJ
Citation: Ga. Wiseman et al., Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with Zevalin, a Y-90-labeled anti-CD20 monoclonal antibody, CLIN CANC R, 5(10), 1999, pp. 3281S-3286S
Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed orrefractory low-grade or follicular non-Hodgkin's lymphoma
Authors: Piro, LD White, CA Grillo-Lopez, AJ Janakiraman, N Saven, A Beck, TM Varns, C Shuey, S Czuczman, M Lynch, JW Kolitz, JE Jain, V
Citation: Ld. Piro et al., Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed orrefractory low-grade or follicular non-Hodgkin's lymphoma, ANN ONCOL, 10(6), 1999, pp. 655-661
Rituximab therapy in Waldenstrom's macroglobulinemia: Preliminary evidenceof clinical activity
Authors: Byrd, JC White, CA Link, B Lucas, MS Velasquez, WS Rosenberg, J Grillo-Lopez, AJ
Citation: Jc. Byrd et al., Rituximab therapy in Waldenstrom's macroglobulinemia: Preliminary evidenceof clinical activity, ANN ONCOL, 10(12), 1999, pp. 1525-1527
Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma:Results of a phase II trial of rituximab
Authors: Davis, TA White, CA Grillo-Lopez, AJ Velasquez, WS Link, B Maloney, DG Dillman, RO Williams, ME Mohrbacher, A Weaver, R Dowden, S Levy, R
Citation: Ta. Davis et al., Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma:Results of a phase II trial of rituximab, J CL ONCOL, 17(6), 1999, pp. 1851-1857
Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsedor refractory CD20(+) B-cell non-Hodgkin's lymphoma
Authors: Witzig, TE White, CA Wiseman, GA Gordon, LI Emmanouilides, C Raubitschek, A Janakiraman, N Gutheil, J Schilder, RJ Spies, S Silverman, DHS Parker, E Grillo-Lopez, AJ
Citation: Te. Witzig et al., Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsedor refractory CD20(+) B-cell non-Hodgkin's lymphoma, J CL ONCOL, 17(12), 1999, pp. 3793-3803
Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
Authors: Czuczman, MS Grillo-Lopez, AJ White, CA Saleh, M Gordon, L LoBuglio, AF Jonas, C Klippenstein, D Dallaire, B Varns, C
Citation: Ms. Czuczman et al., Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy, J CL ONCOL, 17(1), 1999, pp. 268-276
Antibody therapy with Rituximab for patients with low-grade non-Hodgkin's lymphoma
Authors: Dallaire, BK Deardorff, JA White, CA Dowden, S Varns, C Shen, D Grillo-Lopez, AJ
Citation: Bk. Dallaire et al., Antibody therapy with Rituximab for patients with low-grade non-Hodgkin's lymphoma, ONKOLOGIE, 22(3), 1999, pp. 184-190
Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma
Authors: Grillo-Lopez, AJ White, CA Varns, C Shen, D Wei, A McClure, A Dallaire, BK
Citation: Aj. Grillo-lopez et al., Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma, SEMIN ONCOL, 26(5), 1999, pp. 66-73
Rituximab in indolent lymphoma: The single-agent pivotal trial
Authors: McLaughlin, P Hagemeister, FB Grillo-Lopez, AJ
Citation: P. Mclaughlin et al., Rituximab in indolent lymphoma: The single-agent pivotal trial, SEMIN ONCOL, 26(5), 1999, pp. 79-87
Clinical status and optimal use of rituximab for B-cell lymphomas
Authors: McLaughlin, P White, CA Grillo-Lopez, AJ Maloney, DG
Citation: P. Mclaughlin et al., Clinical status and optimal use of rituximab for B-cell lymphomas, ONCOLOGY-NY, 12(12), 1998, pp. 1763-1769
Risultati: 1-21 |